Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Waste Management, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Waste Management, Inc. trades at $226.84 (market cap $90.68B). The key difference: Waste Management, Inc. is far larger — about 3.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Waste Management, Inc. pays a 1.56% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WM | |
|---|---|---|
Market Cap | $29.60B | $90.68B |
Sector | Health | Industrials |
52-Week High | $491.22 | $246.51 |
52-Week Low | $205.48 | $196.77 |
Enterprise Value | $27.56B | $113.47B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
WM trades at $226.19, down 0.18% today, with a neutral technical signal and strong fundamentals. Recent Q2 2026 earnings beat estimates at $2.02 per share, driven by pricing discipline and margin gains. Revenue growth is steady, with 2025 revenue at $25.20 billion, though net income margin dipped to 10.74%. The stock shows a bullish analyst consensus with a $263.43 price target, supported by 20 buy ratings and no sell recommendations. Institutional activity includes mixed trades, such as Bank of America reducing holdings by 6.1% in Q1 2026 (SEC filing, 2026-08-01).
Outlook remains positive due to consistent earnings beats and operational efficiency, but risks include high valuation ratios like a P/E of 59.74 and rising debt levels, with total liabilities at $36.31 billion in 2024. Investors should weigh growth potential against margin pressures and macroeconomic headwinds affecting waste volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
